Cognitive Control Training as an Adjunct to Behavioral Activation Therapy in the Treatment of Depression

NCT ID: NCT01694719

Last Updated: 2012-09-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the potential effects of a cognitive training program when combined with a particular form of psychotherapy (behavioral activation therapy) for depression. Behavioral activation therapy targets changes in behavior as a method for improving a depressed individual's thoughts, feelings, and overall quality of life. This study is designed to test whether a computerized brain exercise called cognitive control training can enhance the effects of a 5-session behavioral activation therapy program. CCT has been shown to reduce depressive symptoms in two other studies, but it has not yet been combined with behavioral activation therapy. The investigators hypothesize that individuals assigned to the behavioral activation plus cognitive control training condition will demonstrate reduced depressive symptoms from pre to post treatment compared with those assigned to the behavioral activation plus computerized control condition. The investigators hypothesize that these gains will be maintained at one-month follow up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Depression Major Depressive Disorder Behavioral Activation Cognitive Training

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Behavioral Activation + Cognitive Control Training

Participants will receive 5 sessions of behavioral activation therapy concurrent with 4 sessions of cognitive control training, a computerized intervention which targets cognitive control processes such as working memory and attention.

Group Type EXPERIMENTAL

Brief Behavioral Activation Treatment for Depression

Intervention Type BEHAVIORAL

Cognitive Control Training

Intervention Type BEHAVIORAL

Behavioral Activation Therapy plus Control Task

Participants will receive 5 sessions of behavioral activation therapy and 4 sessions of a non-active, computerized control task.

Group Type ACTIVE_COMPARATOR

Brief Behavioral Activation Treatment for Depression

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brief Behavioral Activation Treatment for Depression

Intervention Type BEHAVIORAL

Cognitive Control Training

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults ages 18-65
2. Primary psychiatric diagnosis of major depressive disorder
3. Ability to read and speak English sufficiently to complete study procedures
4. If taking antidepressant or anxiolytic medication, participants must be taking a stabilized dose for a minimum period of at least 8 weeks prior to entry into the study
5. Willingness and ability to comply with the requirements of the study protocol

Exclusion Criteria

1. Lifetime history of bipolar disorder or psychotic disorder
2. Neurological disorder such as Parkinson's disease or traumatic brain injury
3. Alcohol or substance dependence within the past 6 months
4. Substantial suicide risk
5. Concurrent psychotherapy initiated within 2 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the depression other than general supportive therapy
6. Current use of antipsychotics, stimulants, or modafinil
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Samantha Moshier, M.A.

Doctoral Candidate in Psychology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boston University - Translational Research Program

Boston, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Samantha J Moshier, M.A.

Role: CONTACT

Phone: 617-358-4311

Email: [email protected]

Michael W Otto, Ph.D.

Role: CONTACT

Phone: 617-353-9610

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Samantha Moshier, M.A.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2930

Identifier Type: -

Identifier Source: org_study_id